PTC Therapeutics (NASDAQ: PTCT) saw its stock price surge 6.79% in after-hours trading on Tuesday following the release of its impressive third-quarter 2025 financial results. The biopharmaceutical company, focused on rare diseases, reported earnings that significantly exceeded analyst expectations.

For the quarter ended September 30, 2025, PTC Therapeutics reported total revenue of $211.0 million, a 7.23% increase from the same period last year and well above the analyst consensus estimate of $185.251 million. The company's earnings per share (EPS) of $0.20 marked a dramatic turnaround from a loss of $1.39 per share in the previous year, beating the analyst estimate of a $1.42 loss by an impressive 114.09%.

The strong performance was driven in part by the successful launch of Sephience, which generated global revenue of $19.6 million and saw 521 start forms in the US by quarter-end. Additionally, the company reported net income of $15.9 million, a significant improvement from the $106.7 million loss in the same quarter of 2024. In light of these results, PTC Therapeutics narrowed its full-year 2025 revenue guidance to $750-$800 million, signaling confidence in its continued growth trajectory.